posted on 2023-04-04, 01:43authored byCarmen A. Widmer, Ismar Klebic, Natalya Domanitskaya, Morgane Decollogny, Denise Howald, Myriam Siffert, Paul Essers, Zuzanna Nowicka, Nadine Stokar-Regenscheit, Marieke van de Ven, Renske de Korte-Grimmerink, José A. Galván, Colin E.J. Pritchard, Ivo J. Huijbers, Wojciech Fendler, Conchita Vens, Sven Rottenberg
Primer sequences used for Lrrc8a or Lrrc8d knockout control in 2D cell lines or Lrrc8d knockout mice or reconstitution experiments
Funding
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (SNF)
EC | ERC | HORIZON EUROPE European Research Council (ERC)
Krebsliga Schweiz (Swiss Cancer League)
Wilhelm Sander-Stiftung (Wilhelm Sander Foundation)
History
ARTICLE ABSTRACT
We demonstrate that lack of expression of Lrrc8a or Lrrc8d significantly reduces the uptake and efficacy of cisplatin and carboplatin in Pt-sensitive BRCA1;p53-deficient tumors. Moreover, our work provides support to confirm the LRRC8A and LRRC8D gene expression in individual tumors prior to initiation of intensive Pt-based chemotherapy.